Literature DB >> 1759826

Antifungal activity of HWA-138 and amphotericin B in experimental systemic candidiasis.

K M Wasan1, K Vadiei, D R Luke, A Keyhani, R A White, T J McQueen, R Mehta, G Lopez-Berestein.   

Abstract

HWA-138, a pentoxifylline analog, has been shown to increase yeast urinary clearance and to reduce yeast counts in the kidneys of rats infected with Candida albicans. Furthermore, HWA-138 has also been shown to prevent amphotericin B-induced acute renal failure in rats. We report here on the effects of HWA-138 alone and in combination with amphotericin B in the treatment of systemic candidiasis in mice. When single doses of HWA-138 were administered intravenously (10, 25, or 50 mg/kg of body weight) into infected mice, no significant improvement in survival was observed. In infected mice treated intravenously with multiple doses of HWA-138 (10, 25, or 50 mg/kg once daily for 5 consecutive days), a significant increase in survival time was seen only in animals also receiving 25 mg of HWA-138 per kg (14 +/- 3 days test versus 9 +/- 1 days control; P less than 0.05). The coadministration of subtherapeutic doses of amphotericin B and HWA-138 resulted in increased survival time. Combination therapy with amphotericin B (0.1-mg/kg single dose) and HWA-138 (10-, 25-, or 50-mg/kg multiple doses) resulted in a significant increase in survival time over controls (19 +/- 4, 19 +/- 5, and 21 +/- 9 days, respectively, versus 9 +/- 3 days; P less than 0.05). Combination therapy with amphotericin B (0.2-mg/kg single dose) and HWA-138 (10-, 25-, or 50-mg/kg multiple doses) also resulted in a significant increase in survival time over controls (24 +/- 6, 24 +/- 6, and 24 +/- 6, respectively, versus 9 +/- 3 days; P less than 0.05). Combination therapy with amphotericin B (0.2-mg/kg single dose) and HWA-138 (10-, 25-, or 50-mg/kg multiple doses) also resulted in a significant increase in survival time over controls (24 +/- 6, 24 +/- 6, and 24 +/- 6, respectively, versus 9 +/- 3 days; P < 0.05). Variance analysis of these findings indicate synergistic activity between amphotericin B and HWA-138 in the treatment of experimental candidiasis in mice.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1759826      PMCID: PMC245323          DOI: 10.1128/AAC.35.10.2046

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Theophylline: a new concept of nephroprotection in acute cyclosporin A nephrotoxicity?

Authors:  P M Rob; J Fandrey; W Jelkmann
Journal:  Klin Wochenschr       Date:  1989-06-15

2.  Effect of pentoxifylline on neutrophil behaviour: stimulation of movement without adhesion changes.

Authors:  K V Crocket; J M Lackie; A A Rogers
Journal:  Biomed Pharmacother       Date:  1988       Impact factor: 6.529

3.  Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function.

Authors:  J L Burgess; R Birchall
Journal:  Am J Med       Date:  1972-07       Impact factor: 4.965

4.  Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor.

Authors:  D E Hammerschmidt; D Kotasek; T McCarthy; P W Huh; G Freyburger; G M Vercellotti
Journal:  J Lab Clin Med       Date:  1988-08

5.  Effects of pentoxifylline in experimental acute renal failure.

Authors:  K Vadiei; L J Brunner; D R Luke
Journal:  Kidney Int       Date:  1989-09       Impact factor: 10.612

6.  Prevention of cyclosporine-induced nephrotoxicity with pentoxifylline.

Authors:  L J Brunner; K Vadiei; L V Iyer; D R Luke
Journal:  Ren Fail       Date:  1989       Impact factor: 2.606

7.  Effect of aminophylline on cisplatin nephrotoxicity in the rat.

Authors:  H T Heidemann; S Müller; L Mertins; G Stepan; K Hoffmann; E E Ohnhaus
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

8.  Adverse effect of amphotericin B administration on renal hemodynamics in the rat. Neurohumoral mechanisms and influence of calcium channel blockade.

Authors:  J P Tolins; L Raij
Journal:  J Pharmacol Exp Ther       Date:  1988-05       Impact factor: 4.030

9.  Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline.

Authors:  G W Sullivan; H T Carper; W J Novick; G L Mandell
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

View more
  4 in total

1.  Comparative studies on the postantifungal effect produced by the synergistic interaction of flucytosine and amphotericin B on Candida albicans.

Authors:  G M Scalarone; Y Mikami; N Kurita; K Yazawa; M Miyaji
Journal:  Mycopathologia       Date:  1992-12       Impact factor: 2.574

2.  Pentoxifylline modulates activation of human neutrophils by amphotericin B in vitro.

Authors:  G W Sullivan; H T Carper; G L Mandell
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

3.  A Neonatal Murine Escherichia coli Sepsis Model Demonstrates That Adjunctive Pentoxifylline Enhances the Ratio of Anti- vs. Pro-inflammatory Cytokines in Blood and Organ Tissues.

Authors:  Esther M Speer; Elizabet Diago-Navarro; Lukasz S Ozog; Mahnoor Raheel; Ofer Levy; Bettina C Fries
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

4.  Pentoxifylline Alone or in Combination with Gentamicin or Vancomycin Inhibits Live Microbe-Induced Proinflammatory Cytokine Production in Human Cord Blood and Cord Blood Monocytes In Vitro.

Authors:  Esther M Speer; Elizabeth Diago-Navarro; Lukasz S Ozog; David J Dowling; Wei Hou; Mahnoor Raheel; Bettina C Fries; Ofer Levy
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.